Cite
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
MLA
Furuse, Junji, et al. “Liposomal Irinotecan with Fluorouracil and Leucovorin after Gemcitabine-Based Therapy in Japanese Patients with Metastatic Pancreatic Cancer: Additional Safety Analysis of a Randomized Phase 2 Trial.” Japanese Journal of Clinical Oncology, vol. 53, no. 2, Feb. 2023, pp. 130–37. EBSCOhost, https://doi.org/10.1093/jjco/hyac177.
APA
Furuse, J., Ueno, M., Ikeda, M., Okusaka, T., Teng, Z., Furuya, M., & Ioka, T. (2023). Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. Japanese Journal of Clinical Oncology, 53(2), 130–137. https://doi.org/10.1093/jjco/hyac177
Chicago
Furuse, Junji, Makoto Ueno, Masafumi Ikeda, Takuji Okusaka, Zhaoyang Teng, Momoko Furuya, and Tatsuya Ioka. 2023. “Liposomal Irinotecan with Fluorouracil and Leucovorin after Gemcitabine-Based Therapy in Japanese Patients with Metastatic Pancreatic Cancer: Additional Safety Analysis of a Randomized Phase 2 Trial.” Japanese Journal of Clinical Oncology 53 (2): 130–37. doi:10.1093/jjco/hyac177.